Merck
$78.409876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$78.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.33 (+1.73%) As of 5:49 PM UTC today
Why Robinhood?
You can buy or sell Merck and other stocks, options, and ETFs commission-free!
About MRK
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ. The listed name for MRK is Merck & Co., Inc.
CEO
Kenneth C. Frazier
Employees
71,000
Headquarters
Kenilworth, New Jersey
Founded
1891
Market Cap
200.32B
Price-Earnings Ratio
17.73
Dividend Yield
3.09
Average Volume
10.86M
High Today
$78.51
Low Today
$77.07
Open Price
$77.14
Volume
6.29M
52 Week High
$89.20
52 Week Low
$65.25
Collections
MRK News
BenzingaJan 26
Merck Drops COVID-19 Vaccine Studies After Phase 1 Data Churn Out Inferior Efficacy Results
Merck & Co., Inc. (NYSE: MRK), which was a late entrant to the COVID-19 vaccine fray, has dropped out of the race, and has instead opted to channelize resources
Analyst Ratings
77%
of 22 ratings
Buy
77%
Hold
23%
Sell
0%
MRK Earnings
$0.00
$0.58
$1.16
$1.74
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 4, Pre-Market
You May Also Like
More MRK News
BenzingaJan 25
ROCE Insights For Merck & Co
Merck & Co (NYSE:MRK) posted a 0.42% decrease in earnings from Q2. Sales, however, increased by 15.44% over the previous quarter to $12.55 billion. Despite the
ReutersJan 25
US STOCKS-Nasdaq futures jump, Merck keeps Dow, S&P 500 subdued
* Merck falls after ending COVID-19 vaccine program
* Investors optimistic about mega-cap company earnings
* GameStop shares surge in short-squeeze
* Futures
